When do biologic drug patents expire and when will biosimilars launch?

United States Patent 9,707,154: What claims cover and how strong is the US patent estate for the ranibizumab/vaccine/secukinumab/serelaxin “glass container stability” composition

Bottom line: US 9,707,154 is directed to a pharmaceutical product where the active agent can be one of several biologics/drugs (ranibizumab; meningococcal group B vaccine, rDNA component adsorbed; AIN457 as secukinumab; or serelaxin) packaged in a specific high-performance glass container defined by quantitative glass chemistry and mechanical stress/layer depth parameters. The patent’s practical enforceability depends less on the biologic identity and more on whether an accused product uses the same glass composition window and compression-layer performance metrics (MPa and µm), including variants for boron-free and layer architecture.

Because the claim set is broad on “pharmaceutical product comprising” (multiple actives) but narrow on glass composition ranges and container stress/layer depth, the key risk for generics/biosimilars is not biochemical substitution but container IP freedom-to-operate: whether standard commercial vials/syringes can be shown to fall outside the claimed glass window or outside the compressive stress/depth thresholds.

What is the core claim scope of US 9,707,154 (pharmaceutical product + high-compression glass container)?

Featured snippet answer: Claim 1 defines a pharmaceutical product comprising a specified biologic/drug plus a glass pharmaceutical container made of a restricted multi-oxide glass (SiO₂, alkaline earth oxides MgO/CaO with CaO ≤ 1.0 mol%, Al₂O₃ at 5–7 mol%, Na₂O > 8 mol%, and a B₂O₃-related ratio limit). Dependent claims then add performance requirements tied to compressive stress (150/250/300 MPa) and layer depth (10+ to 35+ µm), plus boron-free and layer homogeneity features.

Claim 1: chemistry-limited glass + permissive active selection

Claim 1 requires:

Active agent (one of several):
- ranibizumab
- meningococcal group B vaccine [rDNA component, adsorbed]
- AIN457 (secukinumab)
- serelaxin
Glass container made from a glass composition with quantitative constraints:
- SiO₂: 72–78 mol%
- Alkaline earth oxides containing both MgO and CaO
  - CaO ≤ 1.0 mol%
  - ratio: ( \frac{\text{CaO (mol%)}}{\text{CaO (mol%)}+\text{MgO (mol%)}} \le 0.5 )
- Al₂O₃: X mol% where 5 ≤ X ≤ 7
- Alkali oxide comprises Na₂O where Na₂O > 8 mol% (Y is total alkali oxide, but Na₂O is singled out)
- ratio constraint:
  - ( \frac{\text{B₂O₃ (mol%)}}{(Y - X)} \le 0.3 )

Critical interpretation points for infringement/validity:

The active agent identity is not chemically tied to the glass chemistry. This pushes the patent into a container-based formulation/packaging theory: product identity can be broad while the container is the limiting structure.
The B₂O₃ ratio limit in claim 1 is a relative constraint tied to (Y − X), which matters if an accused glass changes not just B₂O₃ content but also overall alkali and alumina levels.
Claim 1 does not state a categorical “boron-free” condition. That appears in dependent claim 7 onward.

Dependent claims: mechanical performance and structural layer features

Claim 2: compressive stress ≥ 150 MPa
Claim 3: compressive stress ≥ 250 MPa
Claim 4: depth of layer > 30 µm
Claim 5: product has increased stability, product integrity, or efficacy (a functional/utility limitation)
Claim 6: combines:
- compressive stress ≥ 150 MPa
- depth of layer > 10 µm
- increased stability/product integrity/efficacy
Claim 7: glass container is substantially free of boron, plus increased stability/product integrity/efficacy
Claim 8: claim 7 plus:
- compressive stress ≥ 150 MPa
- depth of layer > 25 µm
Claim 9: claim 8 plus:
- compressive stress ≥ 300 MPa
- depth of layer > 35 µm
Claim 10: substantially homogeneous inner layer
Claim 11: claim 10 plus:
- compressive stress ≥ 150 MPa
- depth of layer > 25 µm
Claim 12: internal homogeneous layer (broader than claim 10’s “substantially homogeneous inner layer” phrasing)

Critical interpretation points:

The “increased stability/product integrity/efficacy” language in claims 5–6–7 is likely intended to bolster non-obviousness and utility. In litigation, it can become a battleground for claim construction (what constitutes “increased” and what is compared to what baseline).
Mechanical metrics (MPa and µm) are measurable and often lend themselves to:
- straightforward expert testing for infringement,
- clear design-around arguments (e.g., lowering compressive stress below threshold, using thinner/composition outside the window).

Which actives are covered: ranibizumab, meningococcal group B vaccine (rDNA adsorbed), secukinumab (AIN457), and serelaxin?

Featured snippet answer: The patent is not limited to one product. Claim 1 includes a set of actives spanning oncology/ophthalmology (ranibizumab), vaccines (MenB rDNA adsorbed), autoimmune/biologic (secukinumab), and cardiovascular/heart failure drug class (serelaxin). The container chemistry and stress features are the real differentiator.

How this affects freedom-to-operate for biosimilars/generics

Biosimilar strategy: switching from one biologic to a biosimilar does not automatically avoid infringement if the packaging matches the claims. The biologic can be substituted so long as the accused product falls within the claim’s “comprising” active list and the container is within the specified glass/scaffold.
Container strategy: a manufacturer could potentially avoid by:
- changing glass composition outside the constrained oxide ranges/ratios, or
- avoiding the boron-free configuration where dependent claims require it, and/or
- reducing compressive stress or layer depth below the claimed thresholds.

Litigation posture implied by claim architecture

The claim style supports a packaging-centric infringement theory. That usually increases:

relevance of vial/container suppliers as third-party discovery targets,
importance of spec sheets and manufacturing records for glass melt and tempering/ion exchange processes that generate compressive layers.

What glass chemistry is required in claim 1 (SiO2/Al2O3/Na2O/MgO-CaO/B2O3 ratios)?

Featured snippet answer: Claim 1’s glass is a narrowly defined soda-lime(-magnesia)-aluminosilicate-like system with SiO₂ 72–78 mol%, Al₂O₃ 5–7 mol%, Na₂O > 8 mol%, CaO ≤ 1.0 mol% with CaO/(CaO+MgO) ≤ 0.5, and a B₂O₃ relative cap (B₂O₃/(Y-X) ≤ 0.3).

Chemistry window recap (claim 1)

SiO₂: 72–78 mol%
CaO: ≤ 1.0 mol%
MgO: present with CaO, with:
- ( \frac{\text{CaO}}{\text{CaO}+\text{MgO}} \le 0.5 )
Al₂O₃: 5–7 mol%
Na₂O: > 8 mol% (as the alkali oxide constituent)
B₂O₃ ratio limit: ( \frac{\text{B₂O₃}}{(Y-X)} \le 0.3 )

Claim construction pressure points

Mol% vs. trace: “substantially free of boron” appears in claim 7, but the exact meaning of “substantially” is not set in the provided text. Courts often require a construction anchored in the specification and prosecution history.
Relative ratios: the B₂O₃ constraint uses (Y − X), tying the limit to combined alkali and alumina. That can defeat simplistic “we use low boron” defenses if the denominator changes with other oxides.

When does the container create infringement risk: how do compressive stress and layer depth thresholds drive design-around?

Featured snippet answer: Dependent claims create escalating container performance thresholds: ≥150 MPa, ≥250 MPa, and ≥300 MPa, with layer depth stepping from >10 µm to >25 µm, up to >35 µm.

Threshold map by dependent claim

Claim	Requirement additions beyond claim 1	Threshold
2	compressive stress	≥150 MPa
3	compressive stress	≥250 MPa
4	layer depth	>30 µm
6	compressive stress + layer depth + increased stability	≥150 MPa; >10 µm
8	boron-free + compressive + layer + increased stability	≥150 MPa; >25 µm
9	boron-free + higher compressive + deeper layer	≥300 MPa; >35 µm
11	homogeneous inner layer + compressive + depth	≥150 MPa; >25 µm
12	internal homogeneous layer	structural layer feature

Design-around logic that typically matters

If a supplier’s glass is outside the oxide windows, no need to argue stress/depth.
If chemistry matches, the key defense is often:
- compressive stress measured by relevant test method, and/or
- whether the “depth of layer” is defined operationally the same way (surface vs. effective depth profile).
“Increased stability/product integrity/efficacy” can be contested on:
- baseline comparator (what is the prior art glass?),
- whether measured improvements correlate to the claimed container features.

What does “substantially free of boron” change legally and technically?

Featured snippet answer: Claim 7 and onward narrow the packaging to a boron-reduced glass and add performance targets. This can be used both ways: as a clearer definition for enforcement and as a clearer design-around target for non-boron or boron-minimized formulations.

How dependent claims tighten scope

Claim 7 adds: “glass pharmaceutical container is substantially free of boron” + stability/product integrity/efficacy
Claims 8 and 9 add both the boron-free condition and strict mechanical thresholds and layer depth:
- ≥150 MPa and >25 µm (claim 8)
- ≥300 MPa and >35 µm (claim 9)

Technical implications for packaging suppliers

To hit the high compressive stress and depth while also being boron-free, suppliers typically rely on specific thermal tempering and/or ion-exchange regimes and specific oxide balance. That aligns enforcement risk with:

proprietary tempering/ion exchange recipes,
evidence of actual glass chemistry metrology (ICP-OES/ICP-MS for oxides, or conversion from elemental analysis to oxide mol% frameworks).

How strong is US 9,707,154 likely to be: claim breadth vs. enforceability

Featured snippet answer: The patent is broad in the active ingredient list but narrow in container composition and mechanical metrics. That usually makes it more enforceable against products packaged in a matching proprietary vial system and less enforceable against products using different glass families or different stress-layer profiles.

Strength drivers

Quantified oxide ranges and ratios in claim 1 provide a concrete claim target.
Dependent claims create multiple “tiers” of required performance, giving the patentee options:
- sue under claim 1 + stress/depth if the product matches,
- sue under more specific boron-free/homogeneity tiers if the accused glass is in that subset.
Packaging-specific claims often benefit from:
- supplier-level evidence,
- document trails (batch records, melting and forming parameters).

Vulnerability drivers

The “increased stability/product integrity/efficacy” elements are functional and may face:
- challenges if improvements are not tied to the claimed differences,
- proof burdens in litigation (and arguments about whether this limitation is satisfied).
Without the patent specification text, the legal strength of “substantially homogeneous inner layer” and “internal homogeneous layer” cannot be evaluated precisely. Those phrases often become claim-construction issues anchored in the specification.

Patent estate and litigation landscape: what is known from the claim text provided (and what cannot be derived here)

No actionable landscape (other US patents, family members, prior art, prosecution history, PTAB outcomes, OR Orange Book listings, or litigation docket numbers) can be generated from the claim text alone. A comprehensive analysis requires bibliographic identity (filing date, priority, assignee, title) and cross-references. The provided excerpt contains only the claim set, not the document metadata needed to map the estate, expiration dates, terminal disclaimers, or related continuing applications.

Accordingly, this analysis focuses strictly on claim scope mechanics and risk levers embedded in the claims themselves.

Key takeaways

Scope is container-first: The claim set is built around a tightly defined oxide mol% glass plus compressive stress and layer depth performance thresholds.
Active ingredient list is broad: ranibizumab, MenB rDNA adsorbed vaccine, secukinumab (AIN457), and serelaxin are recited, so the main design-around lever is the glass container system, not the drug.
Enforcement risk concentrates on proprietary vial performance: claims 2–4 and 6–9 create multiple entry points tied to ≥150/250/300 MPa and >10/>25/>30/>35 µm.
Boron-free variants are the sharpest subset: claims 7–9 add “substantially free of boron,” making boron-reduced glass a focal point for both infringement testing and invalidity/design-around strategies.
Functional utility language can be disputed: “increased stability/product integrity/efficacy” may become a proof and construction battleground.

FAQs

1. Does US 9,707,154 require ion exchange or surface treatment?
The claim text provided does not specify a mechanism (e.g., ion exchange). It requires measured compressive stress and layer depth, which can be achieved by multiple manufacturing routes.

2. If a product uses a non-listed biologic, is it outside the patent?
Based on the claim text, the product must comprise one of the recited actives. If an accused product uses a different active, it may fall outside the literal active-ingredient requirement, assuming other elements match.

3. Can a manufacturer avoid infringement by lowering compressive stress below 150 MPa?
Claim 2 requires ≥150 MPa; claim 6 also requires ≥150 MPa. If compressive stress is below the threshold and the container is not asserted under claim tiers that do not require it, that can reduce infringement risk.

4. How is “depth of layer” likely measured for claims 4/6/8/9?
The claim text requires a depth greater than specified µm values. Exact measurement methodology depends on the patent’s definition in the specification, but infringement typically turns on expert-tested depth profiles consistent with the patent.

5. Is boron-free glass always required for the broadest claim?
No. Boron-free is only required in dependent claim 7 onward. Claim 1 allows boron but limits it through the B₂O₃ ratio constraint.

References

No external sources were cited because the required bibliographic information, patent number metadata, and estate/litigation records are not included in the prompt.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	June 30, 2006	⤷ Start Trial	2034-04-23
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	August 10, 2012	⤷ Start Trial	2034-04-23
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	October 13, 2016	⤷ Start Trial	2034-04-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 9,707,154

Summary for Patent: 9,707,154